Anti diabetic effect of CL 316,243 (a β3-adrenergic agonist) by down regulation of tumour necrosis factor (TNF-α) expression.
OBJECTIVE: Obesity is a risk factor for the development of insulin resistance and is one of the most important contributors to the pathogenesis of type 2 diabetes, which acts mainly through the secretion of adipokines such as TNF-α that may influence insulin sensitivity. TNF-α affects many aspects o...
Main Authors: | Masoud Ghorbani, Mehdi Shafiee Ardestani, Sedigheh Hatami Gigloo, Reza Ahangari Cohan, Davoud Nouri Inanlou, Peyman Ghorbani |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3464262?pdf=render |
Similar Items
-
Apparent histological changes of adipocytes after treatment with CL 316,243, a ß-3-adrenergic receptor agonist
by: Ghorbani M, et al.
Published: (2015-02-01) -
The glucose lowering effects of CL 316,243 dissipate with repeated use and are rescued by cilostamide
by: Kyle D. Medak, et al.
Published: (2022-02-01) -
Comparative Transcriptome Profiling of Cold Exposure and β3-AR Agonist CL316,243-Induced Browning of White Fat
by: Yu Li, et al.
Published: (2021-05-01) -
The β3 Adrenergic Receptor Agonist CL316243 Ameliorates the Metabolic Abnormalities of High-Fat Diet-Fed Rats by Activating AMPK/PGC-1α Signaling in Skeletal Muscle
by: Ding LN, et al.
Published: (2021-03-01) -
Microsatellite Marker Analysis for Laboratory Mice Profiling
by: Reza Ahangari Cohan, et al.
Published: (2019-01-01)